BioSpace News Archive

Ocular Therapeutix, Inc. (NASDAQ:OCUL), today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders, employees and communities

Endologix® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that a correction notice has been issued for the Ovation iX system, that identifies the root cause of polymer leaks.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced three new Board of Director appointments.

The Patient Safety Authority has released its 2019 annual report, offering key insights to inspire change and improve patient safety in Pennsylvania and beyond.

Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced merger with Tocagen Inc. (previously trading on NASDAQ under the symbol ”TOCA”), under which the stockholders of Forte have become the majority owners of Tocagen, and the operations of Forte and Tocagen have combined

AVEO Oncology announced that it has commenced an underwritten public offering of $40.0 million of shares of its common stock.

Guardion Health Sciences, Inc. announced that its Board of Directors has appointed Dr. David Evans, Ph.D. as the Company’s Interim President and Interim Chief Executive Officer effective immediately.

The U.S. Food and Drug Administration is warning health care providers about a newly discovered potential drug interaction related to the investigational antiviral drug remdesivir, which has received emergency use authorization for the treatment of hospitalized COVID-19 patients with severe disease.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant pathogens, announced results of its Annual General Meeting held on June 10, 2020.

Zentalis Pharmaceuticals, Inc. announced that Ahmed Samatar, Ph.D., Senior Vice President of Oncology Research at Zentalis, will present preclinical data on ZN-c5 at the upcoming American Association of Cancer Research Virtual Annual Meeting II taking place June 22-24th.